Targeted therapies: EGFR inhibitors Book Section
| Authors: | Datko, F. M.; Dickler, M. N. |
| Article/Chapter Title: | Targeted therapies: EGFR inhibitors |
| Abstract: | EGFR is a cell surface receptor that binds extracellular ligands, such as EGF, signaling cell growth through the activation of many intracellular signaling pathways The association of EGFR expression with triple-negative breast carcinomas provides a rationale for the investigation of EGFR-targeted therapies in this subset of cancer patients. Cetuximab and panitumumab are monoclonal antibodies that target the extracellular ligandbinding domain of EGFR. Given only modest increases in response rate seen in clinical trials of cetuximab plus cytotoxic therapy, and associated toxicity with the addition of cetuximab, it is important to characterize molecular markers that may predict clinical benefit. EGFR selective small-molecule tyrosine kinase inhibitors, such as erlotinib and gefitinib, bind the intracellular tyrosine kinase domain of EGFR, and inhibit downstream signaling. Results to date with erlotinib and gefitinib in triple-negative breast carcinoma have been disappointing, although studies combining these agents with cytotoxic therapy are currently ongoing. © 2011 Future Medicine Ltd. All rights reserved. |
| Book Title: | Advances in the Management of Triple-Negative Breast Cancer |
| ISBN: | 9781780841069 |
| Publisher: | Future Medicine |
| Publication Place: | London, UK |
| Date Published: | 2011-10-01 |
| Start Page: | 71 |
| End Page: | 80 |
| Language: | English |
| DOI: | 10.2217/ebo.11.25 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 7 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work